Atlas FDA

Thoraflex™ Hybrid

FDA premarket approval P210006/S010 · decided 2025-03-28

Approval details

PMA number
P210006
Supplement
S010
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
Thoraflex™ Hybrid
Generic name
Hybrid stent graft, thoracic aortic lesion treatment
Applicant
Vascutek, Ltd.
Date received
2024-07-10
Decision date
2025-03-28
Days to decision
261 days
Decision code
APPR
Product code
QSK
Advisory committee
Cardiovascular
Expedited review
No
Location
Inchinnan
Statement
approval for a change in the supplier of the bovine gelatin used to impregnate the grafts, implementation of a new sterilization suite, delivery system material changes, shelf-life updates, and other manufacturing changes.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Gelweave™ Vascular Prostheses (K241550)Vascutek, Ltd.2025-02-27
Gelsoft™ Plus Vascular Prostheses (K241070)Vascutek, Ltd.2024-11-15
Vascutek Gelsoft Plus ERS Vascular Graft (K202703)Vascutek, Ltd.2021-04-06
Vascutek Gelseal Patch, Vascutek Gelsoft Patch, Vascutek Thin Wall Carotid Patch (K200955)Vascutek, Ltd.2020-07-08
Gelseal Vascular Grafts, Gelsoft Vascular Grafts, Gelsoft Plus Vascular Grafts (K162803)Vascutek, Ltd.2017-07-14
Gelweave Vascular Grafts (K162794)Vascutek, Ltd.2017-06-30
GELWEAVE BRANCHED VASCULAR GRAFTS WITH RADIOPAQUE MARKERS (K093817)Vascutek, Ltd.2010-01-07
MAXIFLO, TAPERFLO (K092863)Vascutek, Ltd.2009-10-08